Orexigen Therapeutics, a biopharmaceutical company, is focused on the treatment of obesity. Contrave, Orexigen’s lead product candidate, has completed Phase III clinical trials, and a New Drug Application has been submitted and reviewed by the U.S. Food and Drug Administration. The company has additionally reached an agreement with the FDA for a Special Protocol Assessment (SPA) for the Light Study, which is the Contrave cardiovascular outcomes trial. For more information, visit the company’s Web site at www.orexigen.com.

Rodman & Renshaw is a full-service investment bank dedicated to providing corporate finance, strategic advisory, and related services to public and private companies across multiple sectors and regions. Rodman also provides research, sales, and trading services. According to Sagient Research Systems, Rodman has been ranked the #1 Placement Agent in terms of the aggregate number of PIPE and RD financing transactions completed every year since 2005. For more information on Rodman & Renshaw, visit www.rodmanandrenshaw.com.

Let us hear your thoughts below: